GSK's $1B Indian tender offer to open; Aegerion nabs Canadian OK for Juxtapid; Wockhardt profits plummet on FDA move;

@FiercePharma: Feds put Teva's Copaxone, Azilect marketing under FCA microscope. Story | Follow @FiercePharma

@TracyStaton: Best-read story this AM in FiercePharma: FDA panel could give Bayer painkiller an edge over Pfizer. More | Follow @TracyStaton

@EricPFierce: The engagement is off for CFR and Adcock Ingram. Is a spurned suitor in the wings? News | Follow @EricPFierce

@GalenMoore: Painkillers: A heart-risk warning in place since Vioxx could get lifted--for just one drug. Story | Follow @GalenMoore

> GlaxoSmithKline's ($GSK) $1 billion tender offer for an increased stake in its Indian unit will open Feb. 18 and remain so through March 5. Report

> Aegerion Pharmaceuticals' ($AEGR) blood-lipid drug Juxtapid won regulatory approval in Canada. Release

> Indian generics maker Wockhardt saw its fiscal third-quarter profits drop by 29% after the U.S. FDA took action against one of its plants. Report

> SkyePharma is up for a 3 million euro ($4.1 million) milestone payment now that its respiratory drug Flutiform is approved in France. Report

> The Chinese drugmaker Shanghai Fudan Forward won regulatory approval for a private placement of stock. Report

> Zanzibar's president, Ali Mohamed Shein, invited Indian drugmakers to invest in his country. Report

Medical Device News

@FierceMedDev: Hackers broke into the Big 3--and left the door open for months, report says. Story | Follow @FierceMedDev

@MarkHFierce: Yes, med tech industry, you should watch India's regulatory reform process, but regulators aren't exactly rushing. Item | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Check out our special report: The top drug delivery partnerships of 2013. Report from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Researchers at Harvard and MIT develop innovative hearing aid chip. More | Follow @EmilyWFierce

> WSJ: Device VC funding drops to 8-year lows, but seeds are in place for a rebound. Story

> Roche + Cancer Genetics will expand cancer molecular Dx testing into warmer waters. Article

> Medtronic faces another pretrial setback over its Infuse bone growth implant. News

Biotech News

@FierceBiotech: Can Sanofi's partnership with Regeneron redeem the French biotech's R&D reputation? Read | Follow @FierceBiotech

@JohnCFierce: J&J team marks another setback on depression as mid-stage study flops. Story | Follow @JohnCFierce

@DamianFierce: Merck takes aim at Sanofi with a Lantus biosimilar of its own. More | Follow @DamianFierce

@EmilyMFierce: Gates Foundation delivers an $11.8M grant to fuel tuberculosis R&D. News | Follow @EmilyMFierce

> FDA reviewers paint radically contrasting pictures of The Medicines Co.'s cangrelor. Piece

> Antibiotics developer Melinta lands a $70M round for PhIII development blitz. Story

CRO News

> Covance's sales soar on a jump in late-stage testing. News

> AstraZeneca spares its WuXi-partnered drug in an R&D slash and burn. Story

> BioOutsource doubles its capacity in a bet on the biosimilars boom. Article

> Wellcome bets $4M on CRO Selcia's university team-up. News

> BioClinica plots an EU expansion in the midst of its latest merger. Article

> Report: CRO biz set for another boom. Item

Biotech IT News

> Report: Boston Scientific, Medtronic and St. Jude's networks hacked last year. Story

> Big Pharma players team with NIH to build a diabetes genomics database. Article

> The FDA is making adverse event and recall data available to app developers. Story

> U.K.'s medical research council commits $52M to medical record bioinformatics. News

> The FDA will break up its electronic submission guidance into a series of documents. Article

> Oracle is bringing Siri-like speech recognition to clinical trials. Item

And Finally... Jazz Pharmaceuticals ($JAZZ) broke ground on its new R&D and manufacturing facility in Ireland. Report

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.